IVISense™ 2-DeoxyGlucosone (DG) (XenoLight™ 2-DG) fluorescent imaging probes in RediJect™ Solution enable in vivo targeting of tumors that typically exhibit elevated glucose uptake rate in comparison to surrounding tissues. To achieve maximum glucose targeting and enhanced tumor uptake, these probes have been designed to contain four 2-DG molecules per dye molecule.
IVISense 2-DG probes are available in either 1 or 4 vial quantities and come in a convenient, ready-to-use injectable format.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense 2-DG control dye in RediJect Solutions is a non-reactive dye that can be used as a negative control when using the IVISense 2-DG-750 fluorescent imaging probe.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Arthritis, Inflammation, Oncology/Cancer|
|Wave Length||750 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best p ...
XenoLight RediJect 2-DeoxyGlucosone (DG)-750 is a fluorescent,probe for in vivo targeting of tumors that typically exhibit elevated,glucose uptake rate in comparison to surrounding tissues. To achieve,maximum glucose targeting and enhanced tumor uptake, the probe,has been designed to contain four 2- ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...